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Introduction
Fifty percent of patients with colorectal carcinoma can be
expected to develop metastatic disease [1], while approxi-
mately 20% have isolated hepatic deposits as their index
metastasis [1,2]. In those with hepatic lesions amenable to
resection or surgical ablation, a 3-year survival of up to 60%
can be obtained and a 5-year survival of 25–40% [1,3,4].
These figures compare with a 5-year survival of 1–3% and
a mean survival of 7.5 months in untreated but apparently
resectable hepatic disease [5,6].
Unfortunately, most patients with isolated hepatic
metastasis are not candidates for resection due to wide-
spread disease within the liver. Tumours larger than 3 mm
are preferentially supplied by the hepatic artery in contrast
to hepatic parenchyma [7,8]. Infusion of chemotherapy via
the hepatic artery allows regional delivery of high doses of
the agent without systemic toxicity. Meta-analysis and key
randomised trials have demonstrated at least a doubling of
response rate, significant survival advantage and improved
quality of life when comparing hepatic intra-arterial
chemotherapy to systemic chemotherapy or symptomati-
cally treated controls [2,9,10–13].
The fluropyrimidines floxuridine (FUDR) and
5-flurouracil (5-FU) have high first-pass extraction, allow-
ing large doses to be infused via the hepatic artery with
limited systemic effects. Placement of the arterial catheter
is an operative procedure associated with minimal morbid-
ity, but complications related to the toxicity of the agents
infused are common and contribute to treatment failure
[14].
Duodenal and gastric ulceration can complicate this
type of therapy [15–17]. It has been ascribed to the delivery
of chemotherapeutic agents to the gastroduodenum via
aberrant vessels arising from the hepatic artery, distal to the
infusing catheter [15,18]. The use of methylene blue injec-
tion into the hepatic artery catheter during upper gastroin-
testinal endoscopy has previously been described to detect
unintended perfusion of the duodenum by these vessels
[19,20] for evaluation of patients with pain following
hepatic artery chemotherapy.
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We evaluated the investigation and management of
patients presenting with pain following hepatic intra-
arterial chemotherapy. In particular, methylene blue was
injected via the hepatic catheter port during upper gas-
trointestinal endoscopy (methylene blue endoscopy or
MBE) to diagnose unintended perfusion.
Patients and methods
The Liver Unit database was reviewed, containing prospec-
tive details of patients with hepatic tumours and endoscopy
records. Two hundred and thirty-three hepatic catheters
were placed at our institution for intra-arterial chemother-
apy with either FUDR or 5-FU between September 1995
and December 1998. The 61 patients from this group inves-
tigated for epigastric pain or dyspeptic symptoms by MBE
form the basis of this report. Fifty-nine had catheters placed
either for treatment of unresectable hepatic colorectal
metastasis or for adjuvant therapy in patients at high risk of
recurrence following hepatic resection (n=12) or cryother-
apy (n=13). Of the remaining patients, one had hepatocel-
lular carcinoma and the other a neuroendocrine tumour. In
addition, 9 patients underwent technetium-99m macro-
aggregate albumin scintography after other investigations
proved negative. Extensive attempts to establish the cause
of pain were made in all patients. In those with demon-
strated unintended perfusion, the results of attempted aber-
rant vessel embolisation were recorded, with the aim of
recommencing hepatic arterial chemotherapy.
Hepatic artery catheterisation
The operative technique of catheter placement has been
well described [15,21,22]. The right gastric artery is ligated
and divided, the gastroduodenal artery is dissected out and
controlled. Any arteries arising near the gastroduodenal
origin are ligated, and the catheter is placed so that its tip
lies just within the hepatic artery. Intraoperative perfusion
of the liver and the absence of unintended perfusion are
confirmed by injection of methylene blue via the catheter.
Chemotherapy
Patients with a subcutaneous port received two-weekly
infusional chemotherapy with 5-FU via an external pump,
which delivered 4 g over 4 days, in conjunction with oral
folinic acid 15 mg tds. Patients with implanted pumps
(Infusaid) were given FUDR at 0.18 mg/kg/day (range
0.1–0.3).
Gastroscopy and methylene blue test (MBE)
MBE was performed on all patients presenting with pain
whilst undergoing hepatic infusional chemotherapy. After
examination of the stomach and duodenum, 5 ml methyl-
ene blue was injected into the port over a 15–20 second
interval. The port was then heparinised. A positive result is
determined by instantaneous staining of an area of duode-
num or stomach. Common areas of unintended perfusion
include the first part of the duodenum, antrum, and lesser
curve of the stomach.
Results
There were 233 patients in whom hepatic catheters were
placed during this period for intra-arterial chemotherapy
with either FUDR (63) or 5-FU (170). Sixty-one patients
(26%) developed pain related to chemotherapy infusion and
underwent MBE. There were 43 men and 18 women, with a
mean age of 59 (37–79) years. Twenty of these patients had
rapid blue staining of the stomach or duodenum at
endoscopy (Table 1). Seven with positive MBE had ulcera-
tion at endoscopy. Fifty-five had catheter contrast radiology
(portocathogram) before endoscopy, but in only one patient
was unintended perfusion suggested by this investigation.
Fifteen patients with a positive MBE underwent subse-
quent hepatic artery angiography, confirming an aberrant
artery supplying the gut in 13; two patients had no signifi-
cant vessel demonstrated. The identified vessels were suc-
cessfully embolised in 11 of the 13 patients, and
chemotherapy was recommenced after repeat MBE without
recurrence of gastroduodenal toxicity. Repeated embolisa-
tion attempts in 2 patients were unsuccessful due to
technical inaccessibility of the misperfusing vessel. The 2
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Table 1. Outcome of patients with positive methylene blue
endoscopy (MBE)
Positive MBE Comment
20 blue staining endoscopy 9% of total, 33% of those 
with pain
13 aberrant vessels causing 6% of total, 21% of those 
unintended perfusion with pain
11 successfully treated by 85% of those with aberrant
angiography/embolisation vessels
14 of 20 recommenced 70% of those with
chemotherapy MBE
6 of 20 did not restart 2 failed embolisaton, 3 
chemotherapy catheter migration, 1 
disease progression.
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patients with vessels that could not be embolised had early
recurrence of pain despite changing chemotherapeutic
agents. The location of the aberrant vessels is listed in
Table 2. Eight of these vessels were located beyond the
scope of our dissection, but could have been found by skele-
tonisation of the hepatic artery.
Of the remaining 5 patients with a positive MBE, three
had leakage of methylene blue directly into the duodenum
related to erosion of the catheter into the duodenal wall.
One had partial hepatic artery thrombosis secondary to
arteritis causing retrograde flow of dye along the hepatic
artery. On re-examination 6 weeks later the arteritis had
resolved, and a subsequent MBE failed to demonstrate
unintended perfusion; chemotherapy was recommenced
successfully. The final patient, who was undergoing
chemotherapy for neuroendocrine metastasis, had disease
progression and was changed to octreotide.
Forty-one patients had a negative MBE, of whom 17
had other pathology detected at endoscopy. Three patients
had ulcers without unintended perfusion, one associated
with an underlying inflammatory collection from extrava-
sation of the chemotherapy agent. Of 4 patients with
oesophagitis at endoscopy, one had candidiasis and the
others had additional non-endoscopic pathology (catheter
sepsis, biloma collection, arteritis). Ten patients had
gastritis/duodenitis, and two of these had other concurrent
pathology (catheter sepsis, arteritis).
Of the 24 patients without positive findings at
endoscopy, most had pathology determined by other inves-
tigations. Ten patients had catheter problems consisting of
leak (n = 2), arteritis (n = 6), pseudoaneurysm (n = 1) or
sepsis (n = 2). Three patients had liver collections, five
had sclerosing cholangitis secondary to FUDR, one had
ischaemic chest pain from 5-FU and a final patient
had pain secondary to involution of hepatic metastases.
In 8 patients no cause for the symptoms was established.
No patients with an initial negative MBE went on to
develop unintended perfusion, despite repeat endoscopy.
Operative findings
Approximately one third of the 61 patients in this series
had aberrant arterial anatomy demonstrated at operation
(eight accessory right and 11 accessory left hepatic arter-
ies), but none of these patients developed unintended
perfusion postoperatively. Of the 9 patients (15%) with
unintended perfusion of the duodenum demonstrated intra-
operatively, seven had successful ligation of the offending
vessel. One patient went on to have subsequent embolisa-
tion of a small artery not located during operation before
starting on chemotherapy, while the other developed pain
and ulceration during the first course of chemotherapy due
to a residual misperfusing vessel.
Time to symptoms
Most patients with unintended gastroduodenal perfusion by
chemotherapy presented with pain within 6 months of
catheter placement.
Discussion
Of the many potential complications following hepatic
arterial chemotherapy, gastroduodenal ulceration second-
ary to unintended perfusion is important as a potentially
avoidable cause of morbidity. Most patients presenting with
symptoms suggestive of ulceration have another cause for
pain, but endoscopy remains a central part of their evalua-
tion, 37 (61%) of patients in this series having an endo-
scopic diagnosis. The occurrence of gastric or duodenal
ulceration following hepatic artery infusional chemother-
apy has been well described, but its relationship to aberrant
arterial anatomy has not. In this series, patients with
aberrant vessels perfusing the duodenum were able to avoid
further gastroduodenal toxicity following successful emboli-
sation. Those with failed embolisation suffered recurrent
symptoms and ulceration.
Preoperative angiography is not performed routinely in
our unit. Although some feel that detailed knowledge of
anatomic variants is important before operation, we feel
that the anatomy becomes clear during dissection or after
methylene blue injection. Larger misperfusing or aberrant
vessels can be dissected out and ligated intraoperatively
Table 2. Aberrant vessels causing unintended perfusion
Origin of vessel Comment
3 proximal to GDA origin Proximal reflux occurs 
with secondary 
vasculitis distal to catheter
insertion
5 around GDA origin or These branches should be
hepatic artery ligated during routine 
dissection
5 around or distal to hepatic Due to limited yield,
artery bifurcation dissection distal to hepatic
artery not routine
GDA = gastroduodenal artery.
[23]. In this series only five misperfusing vessels arose from
near the gastroduodenal origin, within the scope of normal
operative dissection. In addition, our work indicates that a
negative intraoperative methylene blue test does not
exclude the possibility of postoperative unintended
perfusion.
Patients with misperfusing vessels arising proximal to
the catheter insertion (n=3) demonstrate reflux into the
common hepatic artery as an alternate cause of unintended
perfusion. Increased distal resistance to flow from arteritis
would seem a likely initiator of reflux. In our patients
hepatic arteritis is a common phenomenon since most
receive 5-FU infusions. In other published series of hepatic
artery chemotherapy FUDR is usually the agent of choice,
and complications related to arterial toxicity appear to be
less common.
We have also noted the tendency of patients receiving
5-FU to present earlier with unintended perfusion than
those receiving FUDR. In addition, some patients with
misperfusing vessels do not develop ulceration despite pro-
longed infusion with FUDR. These findings support our
belief that the greater tissue toxicity of 5-FU leads to more
rapid development of ulceration than FUDR, but a larger
series would be required to demonstrate statistically
significant differences.
No patient with an initial negative MBE went on to
develop unintended perfusion at a later stage, although
many patients had multiple endoscopies (average 2, range
1–5). This fact establishes the reliability of the test as an
initial investigation. Of 20 patients with a positive MBE,
14* had unintended perfusion due to aberrant vessels. As
no patient was subsequently found to have unintended
perfusion on later investigation by other modalities, the
sensitivity of methylene blue endoscopy was 100% with a
positive predictive value of 70%. The specificity (true neg-
ative rate) was 87%. False-positive MBE was due to overly
rapid injection of dye in 2 patients, but in 3 patients it was
due to catheter erosion through the wall of the duodenum
while in another it was due to distal vessel obstruction by
vasculitis.
During the study period several patients (n=6) pre-
sented with upper gastrointestinal haemorrhage. Hepatic
artery chemotherapy has a recognised association with
bleeding [21,24], but the mechanism has not been
described. It can occur as a result of unintended perfusion-
induced ulceration, but in this series only 1 patient with
unintended perfusion presented with bleeding. In 5
patients bleeding was related to hepatic artery pseudoa-
neurysm (HAPA) or erosion of the catheter through the
hepatic arterial wall, with subsequent fistulation into either
duodenum or bile duct.
The relationship between unintended perfusion and
pseudoaneurysm formation, the most serious complication
of hepatic artery chemotherapy, is not known. In the pres-
ent series only 3 of 14 patients with unintended perfusion
went on to develop a pseudoaneurysm. Clearly the outcome
may have been different if embolisation had not been per-
formed. It is certainly possible that pseudoaneurysms are
not related to unintended perfusion but to localised
chemotherapy leaks with adjacent tissue injury.
In conclusion, our policy (Figure 2) for investigation of
pain associated with hepatic infusional chemotherapy is:
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Figure 1a. Hepatic angiogram before embolisation. An aberrant vessel (large
arrow) arising from the gastroduodenal artery misperfuses the duodenum. Small
arrow denotes hepatic artery catheter.
Figure 1b. Hepatic angiogram after embolisation. Aberrant vessel embolised
with coil (arrow). No further unintended perfusion displayed.
*Includes one patient with neuroendocrine tumour who did not require angiography.
1. Portacathogram to exclude leakage from the catheter
tip – usually into a localised collection
2. Methylene blue endoscopy
3. Hepatic arteriogram to exclude arteritis.
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Figure 2. Protocol for investigation of pain related to hepatic infusional chemotherapy.
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